PaxMedica, Inc.

• US
• PaxMedica, Inc.
• Health Care

PXMD

Offering Team

Pre-IPO Investors

Deal Highlights

We are an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). Antipurinergic therapies target the excess production of purines in cells, which can offset homeostasis and result in an overproduction of cellular adenosine triphosphate (or ATP), the main energy molecule in all living cells.

Our primary focus is currently on the development and testing of our lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and FXTAS. We are also focused on the treatment of HAT, where we are seeking to leverage suramin’s historical use in this indication, and data that we have exclusively licensed directly from certain academic or international government institutions to further PAX-101’s development in the U.S.

We are also pursuing the development of next generation antipurinergic product development candidates for neurodevelopmental indications. These assets include PAX-102, our proprietary intranasal formulation of suramin, as well as other new chemical entities that are more targeted and highly selective antagonists of particular purinergic receptor subtypes. We believe our lead drug candidate (suramin), if approved by the FDA, may be a significant advancement in the treatment of ASD and FXTAS. less

We are an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). Antipurinergic therapies target the excess production of purines in cells, which can offset homeostasis and result in an overproduction of cellular adenosine triphosphate (or ATP), the main energy molecule in al More

Deal Tracker

Stock Price